A comprehensive review11 demonstrates the lack of consensus between IGFBP-3 expression levels and cancer incidence, disease severity, or prognostic survival, although reduced IGFBP-3 expression has been correlated with drug resistance14–16, and IGFBP-3 dosed twice daily reduced tumor growth in vivo17,18. The gene discussed is IGFBP3; the disease is neoplasm.